HUP0100586A2 - Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények - Google Patents

Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények

Info

Publication number
HUP0100586A2
HUP0100586A2 HU0100586A HUP0100586A HUP0100586A2 HU P0100586 A2 HUP0100586 A2 HU P0100586A2 HU 0100586 A HU0100586 A HU 0100586A HU P0100586 A HUP0100586 A HU P0100586A HU P0100586 A2 HUP0100586 A2 HU P0100586A2
Authority
HU
Hungary
Prior art keywords
urinary tract
lower urinary
tract symptoms
pharmaceutical compositions
treating lower
Prior art date
Application number
HU0100586A
Other languages
English (en)
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22663745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0100586(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0100586D0 publication Critical patent/HU0100586D0/hu
Publication of HUP0100586A2 publication Critical patent/HUP0100586A2/hu
Publication of HUP0100586A3 publication Critical patent/HUP0100586A3/hu
Publication of HU230982B1 publication Critical patent/HU230982B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

A találmány férfiakban jóindulatú prosztata-hiperpláziával kapcsolatosalsó húgyúti tünetek kezelésére alkalmas gyógyászati készítményekrevonatkozik, melyek alfa-adrenoreceptor antagonistát és muszkarinantagonistát tartalmaznak. A találmány szerinti készítmények különösenalkalmasak mérsékelt vagy súlyos alsó húgyúti tünetek kezelésére. Ó
HU0100586A 2000-02-09 2001-02-06 Alsó húgyúti tünetek kezelésére alkalmas, egy alfa-adrenoreceptor antagonistát és darifenacint tartalmazó gyógyászati készítmények HU230982B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18131000P 2000-02-09 2000-02-09
US60/181,310 2000-02-09

Publications (4)

Publication Number Publication Date
HU0100586D0 HU0100586D0 (en) 2001-03-28
HUP0100586A2 true HUP0100586A2 (hu) 2001-11-28
HUP0100586A3 HUP0100586A3 (en) 2003-05-28
HU230982B1 HU230982B1 (hu) 2019-08-28

Family

ID=22663745

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100586A HU230982B1 (hu) 2000-02-09 2001-02-06 Alsó húgyúti tünetek kezelésére alkalmas, egy alfa-adrenoreceptor antagonistát és darifenacint tartalmazó gyógyászati készítmények

Country Status (12)

Country Link
US (2) US20010044438A1 (hu)
EP (2) EP1123705A1 (hu)
KR (2) KR20010078803A (hu)
AU (3) AU1832901A (hu)
CA (1) CA2334460C (hu)
HU (1) HU230982B1 (hu)
IL (1) IL141235A (hu)
MY (1) MY164900A (hu)
NZ (1) NZ509807A (hu)
PE (1) PE20011167A1 (hu)
TW (1) TWI287448B (hu)
ZA (1) ZA200101012B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
CA2465110A1 (en) * 2001-11-07 2003-05-15 Synthon B.V. Tamsulosin tablets
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
WO2003103659A1 (ja) * 2002-06-07 2003-12-18 山之内製薬株式会社 過活動膀胱治療剤
EP1551394A1 (en) * 2002-08-14 2005-07-13 Janssen Pharmaceutica N.V. Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
WO2004071533A1 (ja) * 2003-02-14 2004-08-26 Takeda Pharmaceutical Company Limited 局所投与用製剤
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
WO2007010509A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Controlled release pharmaceutical composition comprising alpha-adrenergic antagonist and muscarinic antagonist
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
AR058119A1 (es) * 2005-12-20 2008-01-23 Pfizer Prod Inc Combinacion farmaceutica para el tratamiento de sintomas del tracto urinario inferior (stui)
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
WO2009013846A1 (ja) * 2007-07-20 2009-01-29 Astellas Pharma Inc. 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US7891492B2 (en) * 2007-08-13 2011-02-22 Carton Service, Incorporated Pharmaceutical blister card package
EP2181707A1 (en) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
CN104768540A (zh) * 2012-09-05 2015-07-08 才思制药公司 抗胆碱能神经保护组合物和方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
TWI822690B (zh) * 2017-07-20 2023-11-21 中國大陸商盛元醫藥廣州有限公司 用於治療近視之組合物及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
JPH08502977A (ja) * 1992-11-04 1996-04-02 セプラコア，インコーポレイテッド 良性前立腺増殖およびアテローム性動脈硬化の治療法ならびに（＋）ドキサゾシン組成物
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
WO2001021167A1 (en) * 1999-09-22 2001-03-29 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein

Also Published As

Publication number Publication date
TWI287448B (en) 2007-10-01
CA2334460A1 (en) 2001-08-09
IL141235A0 (en) 2011-08-01
NZ509807A (en) 2002-09-27
AU2006202176A1 (en) 2006-06-15
US20010044438A1 (en) 2001-11-22
AU2009227918B2 (en) 2011-09-22
PE20011167A1 (es) 2001-11-13
US7138405B2 (en) 2006-11-21
IL141235A (en) 2012-04-30
AU1832901A (en) 2001-08-16
CA2334460C (en) 2009-01-27
AU2009227918A1 (en) 2009-11-12
EP2266571A1 (en) 2010-12-29
KR20040032141A (ko) 2004-04-14
KR20010078803A (ko) 2001-08-21
HU0100586D0 (en) 2001-03-28
ZA200101012B (en) 2002-08-06
US20050222165A1 (en) 2005-10-06
HU230982B1 (hu) 2019-08-28
EP1123705A1 (en) 2001-08-16
HUP0100586A3 (en) 2003-05-28
MY164900A (en) 2018-01-30

Similar Documents

Publication Publication Date Title
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
WO2006018743A3 (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
WO2007112288A3 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
DK1419154T3 (da) Rapamycin-29-enoler
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
BR0109931A (pt) Composições farmacêuticas
BG105302A (en) Means for improving cognition
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
TNSN07240A1 (en) Compounds for flaviviridae treatment
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
IL155263A0 (en) Pharmaceutical solutions of modafinil compounds
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
EP1743656A3 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
SE0001916D0 (sv) Novel formulation
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
BE1016292A3 (nl) Verbinding en gebruik bij behandeling.
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERUS LABS LUXCO SARL, LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

HC9A Change of name, address

Owner name: MERUS LABS LUXCO SARL, LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

GB9A Succession in title

Owner name: MERUS LABS LUXCO II S.A R.L., LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; MERUS LABS LUXCO SARL, LU; MERUS LABS LUXCO SARL, LU; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

HC9A Change of name, address

Owner name: MERUS LABS LUXCO II S.A R.L., LU

Free format text: FORMER OWNER(S): PFIZER PRODUCTS INC., US; MERUS LABS LUXCO SARL, LU; MERUS LABS LUXCO SARL, LU; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD., BM

MM4A Lapse of definitive patent protection due to non-payment of fees